Boca Pharmacal, Inc. Receives FDA Approval on Methimazole

CORAL SPRINGS, Fla., March 9, 2012 /PRNewswire/ -- Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Methimazole Tablets USP, 5mg and 10mg, the generic version of King Pharmaceuticals' Tapazole^® Methimazole tablets, indicated to treat hyperthyroidism.

(Photo: http://photos.prnewswire.com/prnh/20120309/FL67393LOGO)

"This is our first approval this year and we are expecting a second before the end of the first quarter," said Robert Edwards, CEO of Boca Pharmacal. "As our pipeline continues to mature and we come to the end of our largest development cycle, Boca expects to have multiple approvals this year."

Boca Pharmacal, Inc.
Since its founding in 1998, Boca Pharmacal's mission has been to offer niche items typically overlooked by many larger generic companies as affordable alternatives to brand-named products.

Using multiple facilities across the globe, Boca Pharmacal has a broad reach and a reliable vertical structure that allows them to develop products that include tablets and capsules, semi-solids, solutions, and suspensions. Boca Pharmacal continues to invest in research and development to ensure a wide and continually expanding variety of offerings. The Boca Pharmacal product line is marketed to chains, wholesalers, distributors, managed markets and government agencies. Boca Pharmacal is located at 3550 NW 126th Avenue, Coral Springs, Florida, 33065. For more information, visit www.bocapharmacal.com.

SOURCE Boca Pharmacal, Inc.